Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589027 | 0.92 | L3MBTL1 (0.48) | L3MBTL1NPC1ALDH1A1MAPTKDM4E | |
| SCHEMBL4387410 | 0.90 | KMT2A (0.53) | AKR1C3L3MBTL1ALDH1A1KDM4ECYP2C9 | |
| SCHEMBL4386137 | 0.88 | GAA (0.53) | AKR1C3L3MBTL1ALDH1A1MAPTCYP2C9 | |
| SCHEMBL4386149 | 0.87 | AKR1C3 (0.52) | AKR1C3L3MBTL1NPC1ALDH1A1CYP2C9 | |
| SCHEMBL8225146 | 0.85 | KMT2A (0.46) | AKR1C3L3MBTL1ALDH1A1MAPTKDM4E | |
| SCHEMBL4387482 | 0.85 | AKR1C3 (0.43) | AKR1C3L3MBTL1NPC1CYP2C9KMT2A | |
| SCHEMBL4393768 | 0.84 | KMT2A (0.47) | AKR1C3NPC1CYP2C9MEN1KMT2A | |
| SCHEMBL4380728 | 0.81 | GAA (0.51) | L3MBTL1ALDH1A1KDM4ECYP2C9MEN1 | |
| SCHEMBL4377730 | 0.81 | GPR183 (0.41) | ALDH1A1CYP2C9POLBMEN1KMT2A | |
| SCHEMBL4384919 | 0.80 | HTT (0.48) | MAPTKDM4ESMN1; SMN2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | AKR1C3 416/4885L3MBTL1 2099/4885NPC1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.